HT 101
Alternative Names: HT-101Latest Information Update: 10 Dec 2024
Price :
$50 *
At a glance
- Originator Suzhou Hepa Thera Biopharmaceutical
- Class Amides; Amino sugars; Antivirals; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Hepatitis B
Most Recent Events
- 05 Jun 2024 Preclinical trials in Hepatitis B in China (SC) before June 2024
- 05 Jun 2024 Efficacy and adverse events data from a phase Ib trial in Hepatitis B presented at the European Association for the Study of the Liver Congress 2024 (EASL-2024)
- 05 Jun 2024 Pharmacodynamics data from a preclinical trial in Hepatitis B presented at the European Association for the Study of the Liver Congress 2024 (EASL-2024)